ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
View Top Employees from ALX Oncology| Website | http://alxoncology.com/ |
| Ticker | ALXO |
| Revenue | $6 million |
| Funding | $105 million |
| Employees | 79 (59 on RocketReach) |
| Founded | 2015 |
| Address | 323 Allerton Ave, South San Francisco, California 94080, US |
| Phone | (650) 466-7125 |
| Technologies |
JavaScript,
HTML,
PHP
+33 more
(view full list)
|
| Industry | Biotechnology Research, Drug Manufacturing & Research, Biopharma, Immuno-Oncology, Pharmaceuticals, Biotechnology, Novel Biologics, Healthcare, Health Care, Research and Development, Science and Engineering, Innovation, Industrial, Life Science, Therapeutics |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular ALX Oncology employee's phone or email?
ALX Oncology Questions
The ALX Oncology annual revenue was $6 million in 2024.
Jason Lettmann is the CEO of ALX Oncology.
59 people are employed at ALX Oncology.
ALX Oncology is based in South San Francisco, California.
The NAICS codes for ALX Oncology are [32541, 32, 325, 3254].
The SIC codes for ALX Oncology are [28, 283].
Top ALX Oncology Employees
-
5+5+
-
12
-
21
-
22
-
11
-
22
-
ViewHadi Falahatpisheh
Vice President, Research And Development at ALX Oncology
South San Francisco, CA, US21 -
21
Related Companies
